According to Pacira Biosciences 's latest financial reports the company's current revenue (TTM) is $0.67 B. In 2022 the company made a revenue of $0.66 B an increase over the years 2021 revenue that were of $0.54 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.67 B | 1.22% |
2022 | $0.66 B | 23.14% |
2021 | $0.54 B | 26.04% |
2020 | $0.42 B | 2.05% |
2019 | $0.42 B | 24.83% |
2018 | $0.33 B | 17.67% |
2017 | $0.28 B | 3.71% |
2016 | $0.27 B | 10.99% |
2015 | $0.24 B | 25.97% |
2014 | $0.19 B | 131.05% |
2013 | $85.55 M | 118.89% |
2012 | $39.08 M | 149.13% |
2011 | $15.68 M | 7.73% |
2010 | $14.56 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Zogenix ZGNX | $81.69 M | -87.90% | ๐บ๐ธ USA |
Recro Pharma
REPH | $75.36 M | -88.84% | ๐บ๐ธ USA |
Omeros Corporation OMER | N/A | N/A | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.10 B | -85.13% | ๐บ๐ธ USA |
Heron Therapeutics HRTX | $0.12 B | -81.18% | ๐บ๐ธ USA |
Cara Therapeutics
CARA | $20.96 M | -96.89% | ๐บ๐ธ USA |